Navigation Links
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Date:7/8/2009

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters.

Conference Call and Webcast Information

To access the live call, please dial 866-543-6408 (domestic) or 617-213-8899 (international) 10 minutes prior to the start time and use the passcode 40038100. A replay of the call will be available at approximately 11:30 a.m. EDT on July 9, 2009 until July 16, 2009. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 48864759. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Nov. 6 Caraco Pharmaceut...nched ketorolac tromethamine ophthalmic solution, ...nd Drug Administration (FDA) for Sun Pharma,s Abbr...ular® opthalmic solution on the first day fol...ac is therapeutically equivalent to Acular® O...
(Date:11/5/2009)..., N.J., Nov. 5 Osteotech...field of biologic products for regenerative healin...quarter ended September 30, 2009. ,, "During th...ase of our three new biologic products MagniFuse(...d Plexur M® Innovative Grafting," said Sam Ow...
(Date:11/5/2009)...ntario, Nov. 5 Helix Bio...unced today that its Phase II trial of Topical Int...warts (AGW) has completed patient enrollment, with...e trial. ,, The double-blind and placebo-contro...s in Germany and Sweden. Patients participating i...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 1Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 2Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 3Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 1Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 3Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 4Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 5Defeating nicotines double role in lung cancer 48187 1Defeating nicotines double role in lung cancer 48187 2Defeating nicotines double role in lung cancer 48187 3
...Overweight and Obese Type 2 Diabetics to Assess Sa...lized Secondary Endpoints, PLYMOUTH MEETING, Pa.,...ay announced that dosing of subjects has,begun in ...se 1 study of,trodusquemine (MSI-1436), in overwei...l therapeutic for the treatment of type 2 diabetes...
...K, Calif., Jan. 16 Cogentus Pharmaceuticals,Inc. ...l study to confirm,the full antiplatelet activity ...68 is a once-daily capsule that combines clopidogr... and Sanofi-Aventis as Plavix(R)) with,a gastropro...al safety of,antiplatelet therapy., (Logo: http:...
Other Medicine Technology:Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436) 2Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436) 3Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436) 4Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168 2
(Date:11/7/2009)...PRNewswire-USNewswire/ -- Speaker Nancy Pelosi sp...62, the Affordable Health Care for America Act. T...t. Below are the Speaker,s remarks. ,, "Madam...ment for our nation and for American families. Fo...itical philosophy -- as far back as Teddy Roosevel...
(Date:11/7/2009)...wire/ -- Calling this a "defining moment" for the ...ent J. James Rohack, M.D., today addressed medical... medical specialty societies at the opening of the...alth system reform will top the agenda. ,, (Log...AMALOGO ) ,, "Over the next 72 hours, this AM...
(Date:11/7/2009)...ewswire-USNewswire/ -- The U.S. bishops November 7...vote for the Stupak-Ellsworth Amendment to the hea...-Kaptur-Dahlkemper-Lipinski-Smith Amendment will k...ng and conscience protections in the Affordable He... ,, The letter was signed by Cardinal Justin Ri...
(Date:11/7/2009)...all youth will rebel, expert says , , SATU...kely to behave badly if their parents expect them ...ieve they are simply being realistic might actuall...ty Buchanan, a psychology professor at Wake Forest...university news release. "Negative expectations on...
(Date:11/7/2009)...et ‘sweatox’ or ‘Boytox’, ...he anti-ageing jab ‘Breastox’ – ...acute;colletage, can reduce the appearance of wrin...e breasts, leaving smoother, younger-looking skin....09 -- Transform, the UK’s largest group of ...
Breaking Medicine News(10 mins):Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:UK Boobs Get a Boost with 'Breastox' 2
...ling should be mercilessly shot down, according to...roup activists. The group’s mandate is to communic...mendation that purports to introduce assisted // s...groups based on faith, and health groups have join...
...expressed their disappointment over the inadequate...transfusions of blood infected with hepatitis C //...tion became available only in 1991, which led many...g demands from campaigners to look into the happen...
... girl died after eating a single sweet as she suff...as a strawberry cream cake but had // failed to id... suddenly developed difficulty in breathing and lo...damage. Five days later, her mother Sandra ...
...and chemistry between new partners wanes anywhere ... by a desire for companionship, according to novel...aly have now been able to place a finger on probab...hormones, responsible for the body Chemistry that ...
...an insight into the 'déjà vu' phenomenon, a sensat...ings before. // Leeds university researchers have ... memory process. Though all of us have experienced...University, saying that he had already witnessed h...
... human beings only as recently as between 13,000 a...The earlier theories contend that the bond // last...d by Darcy Morey, and takes canine burials into co...did not become common between 15,000 and 14,000 ye...
Other Medicine News:Health News:Sex Spell Lasts Two Years Graduating To 'Cuddles' Companionship 2Health News:Mystery Behind The Déjà Vu Phenomenon Yet To Be Resolv 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: